All News

Julie M. Vose, MD, MBA, answered questions about the significance and potential impact of MZL Workshop.

Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.

Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.

Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.

The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.

Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.

Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.

A pathologist discusses the challenges of diagnosing nodal MZL, including its lack of specific defining characteristics.

Amezalpat plus atezolizumab and bevacizumab achieved a 6-month increase for OS compared with atezolizumab and bevacizumab alone in patients with HCC.

Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.

Findings from the ICE3 trial revealed that no serious adverse effects were experienced related to the use of cryoablation in ipsilateral breast tumors.

Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.

Hematologists gathered to discuss recent updates on bispecific antibodies surrounding patients with relapsed/refractory multiple myeloma.

In the phase 2 TRANSCEND FL trial, lisocabtagene maraleucel met its primary end point of overall response rate in patients with marginal zone lymphoma.

Marginal Zone Lymphoma experts discussed recent advancements in all areas of MZL, while calling attention to gaps in knowledge in the 2024 MZL Scientific Workshop.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

A retrospective systemic literature review showed that increased lines of therapy led to decreased HRQOL in patients with relapsed/refractory myeloma.

The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.

Following promising results from a trial investigating the effects of 225Ac-SSO110 on Balb/c nude mice injected with the xenograft model of SCLC, IND clearance was granted by the FDA.

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.

Completion of the phase 1 first-in-human trial revealed that iPSC-derived CAR natural killer cell therapy has potential for development across oncology.

The decision impacts the phase 1 STARLING trial and additional phase 1 trials sponsored by the Moffitt Cancer Center evaluating TIDAL-01 in solid tumors.

Ziftomenib elicited positive responses in patients with NPM1-mutant acute myeloid leukemia, meeting the primary end point of the phase 2 KOMET-001 trial.

Thomas Habermann, MD, discusses the significance of the MZL Workshop and its contributions to advancing research and improving outcomes.

“We have huge amounts of work to do to maximize the efficacy of immunotherapy,” Christine Bestvina, MD, said during an interview with CancerNetwork.

All 9 patients in a phase 1 trial testing a neoantigen-targeting personalized cancer vaccine in renal cell carcinoma had no recurrence at data cutoff.

Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.

Julie M. Vose, MD, MBA, discussed MZL research and future directions in the February Letter to Readers.